$26.59
7.35% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Stock price

$26.59
-0.61 2.24% 1M
+2.61 10.88% 6M
-0.63 2.31% YTD
-2.49 8.56% 1Y
-53.61 66.85% 3Y
+7.84 41.81% 5Y
+7.84 41.81% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-2.11 7.35%
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Key metrics

Market capitalization $2.20b
Enterprise Value $1.44b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.11
P/S ratio (TTM) P/S ratio 6.30
P/B ratio (TTM) P/B ratio 2.77
Revenue growth (TTM) Revenue growth 328.73%
Revenue (TTM) Revenue $349.64m
EBIT (operating result TTM) EBIT $-182.67m
Free Cash Flow (TTM) Free Cash Flow $-145.37m
Cash position $925.76m
EPS (TTM) EPS $-1.76
P/E forward negative
P/S forward 42.89
EV/Sales forward 28.02
Short interest 15.88%
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

10x Buy
56%
8x Hold
44%

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
56%
Hold
44%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
350 350
329% 329%
100%
- Direct Costs 22 22
22% 22%
6%
328 328
512% 512%
94%
- Selling and Administrative Expenses 82 82
104% 104%
24%
- Research and Development Expense 406 406
6% 6%
116%
-161 -161
57% 57%
-46%
- Depreciation and Amortization 22 22
22% 22%
6%
EBIT (Operating Income) EBIT -183 -183
54% 54%
-52%
Net Profit -144 -144
54% 54%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Neutral
GlobeNewsWire
20 days ago
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of  Hemoglobin F
Neutral
GlobeNewsWire
22 days ago
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Neutral
GlobeNewsWire
23 days ago
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinat...
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 436
Founded 2017
Website www.beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today